2006
DOI: 10.1158/1541-7786.mcr-05-0118
|View full text |Cite
|
Sign up to set email alerts
|

A Novel Role of DNA Polymerase η in Modulating Cellular Sensitivity to Chemotherapeutic Agents

Abstract: Genetic defects in polymerase H (pol H; hRad30a gene) result in xeroderma pigmentosum variant syndrome (XP-V), and XP-V patients are sensitive to sunlight and highly prone to cancer development. Here, we show that pol H plays a significant role in modulating cellular sensitivity to DNA-targeting anticancer agents. When compared with normal human fibroblast cells, pol H -deficient cells derived from XP-V patients were 3-fold more sensitive to B-D-arabinofuranosylcytosine, gemcitabine, or cis-diamminedichloropla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
117
1
1

Year Published

2008
2008
2016
2016

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 114 publications
(122 citation statements)
references
References 28 publications
3
117
1
1
Order By: Relevance
“…Although results from yeast suggest that pol η does not confer resistance to ICL by cisplatin [5], XP-V cells have been reported to be hypersensitive to and impaired in the repair of a number of DNA damaging agents, including ICL-forming agents, suggesting that TLS by pol η is important in lesion tolerance and survival following ICL in humans [17,20,32,39]. However, most prior studies of pol η and ICLs have been performed utilizing plasmid substrates, rather than analyzing genomic DNA [18][19][20].…”
Section: Discussionmentioning
confidence: 99%
“…Although results from yeast suggest that pol η does not confer resistance to ICL by cisplatin [5], XP-V cells have been reported to be hypersensitive to and impaired in the repair of a number of DNA damaging agents, including ICL-forming agents, suggesting that TLS by pol η is important in lesion tolerance and survival following ICL in humans [17,20,32,39]. However, most prior studies of pol η and ICLs have been performed utilizing plasmid substrates, rather than analyzing genomic DNA [18][19][20].…”
Section: Discussionmentioning
confidence: 99%
“…hpol is also involved in translesion synthesis of other DNA lesions, e.g. 8-oxodG (29, 30), abasic sites (31, 32), and cisplatin or other therapeutic drug-induced DNA damage (33)(34)(35)(36)(37)(38).In this study, we investigated the ability of hpol to incorporate ribonucleotides into DNA and crystallized hpol with incoming rNTPs opposite both undamaged DNA and an 8-oxodG lesion. Our results demonstrate that hpol can incorporate ribonucleotides into DNA with relatively high selectivity but low efficiency, even when the template strand contains the DNA lesion 8-oxodG or CPD.…”
mentioning
confidence: 99%
“…In addition to skin, pol η is expressed in most tissues (10). The expression of pol η correlates with the effectiveness of anticancer therapeutic agents that exert their activity by introducing DNA lesions that block the progression of DNA replication (11). In addition to exogenous introduced DNA lesions, pol η contributes to genomic stability during unperturbed DNA replication (12) and replicates across reactive oxygen species (ROS)-induced oxidative DNA lesions 8-oxoG (7,8-dihydro-8-oxoguanine), thymine glycol, and lipid peroxidation DNA adducts generated during endogenous metabolic processes (13,14).…”
mentioning
confidence: 99%